Kodiak Sciences stock (US50012K1051): Q4 2025 earnings miss sparks investor focus

Kodiak Sciences reported Q4 2025 EPS of -$0.94, missing estimates by $0.01, as shared in its May 7, 2026 earnings release. Next report due May 13.

Kodiak Sciences Inc. disclosed its Q4 2025 financial results on May 7, 2026, posting an EPS of -$0.94, which fell short of the consensus estimate of -$0.93 by $0.01, MarketBeat as of May 2026. The biotech firm, focused on retinal therapies, continues advancing its pipeline amid ongoing losses typical for clinical-stage companies. Investors await the next earnings on or around May 13, 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Kodiak Sciences Inc
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Ophthalmology, retinal diseases
• Key revenue drivers: Pipeline candidates like KSI-301
• Home exchange/listing venue: Nasdaq (KOD)
• Trading currency: USD

Kodiak Sciences Inc: core business model

Kodiak Sciences Inc develops novel therapeutics for retinal diseases, leveraging proprietary ABC Platform technology to create extended-duration intravitreal therapies. The company's lead candidate, KSI-301, an anti-VEGF antibody biopolymer conjugate, aims to reduce treatment frequency for conditions like wet age-related macular degeneration (AMD) and diabetic macular edema (DME). This approach addresses unmet needs in ophthalmology by potentially offering durability beyond current standards.

Listed on Nasdaq under ticker KOD, Kodiak Sciences operates as a clinical-stage biotech with no approved products generating revenue as of its Q4 2025 report published May 7, 2026. The firm invests heavily in R&D, funding Phase 3 trials and platform expansion, which contributes to its loss-making profile common in the sector.

Main revenue and product drivers for Kodiak Sciences Inc

Future revenue hinges on successful commercialization of KSI-301 and other pipeline assets. The Q4 2025 EPS miss of -$0.94 versus -$0.93 expected underscores R&D burn rate, with full-year 2025 figures detailed in the 10-K filing as of May 7, 2026. Key drivers include trial outcomes, regulatory milestones, and potential partnerships in the $20B+ retinal market.

Pipeline progress remains central, with KSI-301's Day 1 data from prior phases showing extended durability. For US investors, Kodiak's focus on prevalent diseases like AMD, affecting millions domestically, positions it for market relevance if approvals materialize.

Industry trends and competitive position

The ophthalmology biotech space sees intense competition from established players like Regeneron and Roche with Eylea and Lucentis, alongside newcomers pushing long-acting therapies. Kodiak differentiates via its sustained-release platform, potentially capturing share in a market growing at 7% CAGR through 2030 per sector reports.

Why Kodiak Sciences Inc matters for US investors

With Nasdaq listing and therapies targeting US-prevalent retinal conditions, Kodiak offers exposure to biotech innovation. Its pipeline addresses aging population-driven demand, making it noteworthy for portfolios tracking ophthalmology advancements amid broader healthcare spending.

Conclusion

Kodiak Sciences Inc's recent Q4 2025 earnings miss highlights ongoing investment in its retinal therapy pipeline. While losses persist, advancements in KSI-301 keep the company in focus for biotech watchers. US investors may track upcoming May 13 earnings for pipeline updates and financial health indicators.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.